Multiple myeloma is a devastating hematologic cancer that is associated with significant comorbidities plaguing the clinical course of the disease. Recent development in myeloma therapeutics has made a positive impact in overall survival of patients. Several new drugs secured approval from the FDA in the last 5 years bringing renewed hope to patients and caregivers. What remains more promising is the combination of these new agents with traditional anti-myeloma therapies that are clinically demonstrating enhanced activity and improvement in the number of patients achieving complete responses. These high rates of clinical responses question the upfront use of high-dose chemotherapy and autologous stem cell transplant. The future of myeloma therapeutics resides in rational and effective combinations that can target both the tumor cell as well as its microenvironment.
|Original language||English (US)|
|Number of pages||4|
|Issue number||SUPPL. 2|
|State||Published - Sep 13 2007|
ASJC Scopus subject areas